^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Copiktra (duvelisib) (PI3Kδ inhibitor, PI3Kγ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    PRNewswire
    Title:

    COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

    Published date:
    06/09/2021
    Excerpt:
    Secura Bio, Inc...today announced that...the European Medicines Agency granted marketing authorization for COPIKTRA as monotherapy for the treatment of relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in patients, who have received at least two prior therapies and for the treatment of Follicular Lymphoma (FL) that is refractory to at least two prior systemic therapies.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    09/26/2019
    Excerpt:
    COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with...Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    Follicular Lymphoma: Second-line and Subsequent therapy…Other recommended regimens…PI3K inhibitors (relapsed/refractory after 2 prior therapies)…Duvelisib